US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

434.99

+9.002.11%

Number of Gainers:3

Number of Losers:1

Number of Flat:1

PE:- -

High:435.44

Open:425.01

Low:414.20

Close:425.99

Volume:10.92M

Turnover:150.55M

Market Cap:9.28B

Float Cap:8.53B

Loading ...

Intellia Therapeutics reports inducment grants

Intellia Therapeutics Awards Inducement Grants to New Employees

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Beam Therapeutics announces upcoming board member resignation

Beam Therapeutics Director Carole Ho Resigns

What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders

Simply Wall St.

FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang

Simply Wall St.

Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor

Sangamo Therapeutics Begins Rolling BLA Submission to FDA for Fabry Disease Gene Therapy

BUZZ-U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW

Sangamo says principal financial officer Prathyusha Duraibabu terminated

Sangamo names Nikunj Jain as interim CFO, principal financial officer

Sangamo prices 35.2M shares at 47.19c in underwritten offering

Sangamo Therapeutics Prices $25 Million Offering with Warrants and Share Rights

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

THOMSON REUTERS

BRIEF-Sangamo Therapeutics Inc - On Feb 2, Prathyusha Duraibabu Terminated As Principal Financial Officer - SEC Filing

Sangamo Therapeutics Inc - on Feb 2, Prathyusha Duraibabu Terminated as Principal Financial Officer - SEC Filing

THOMSON REUTERS

Sangamo Therapeutics ernennt Nikunj Jain zum Interim-Finanzchef

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial

Simply Wall St.

IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":434.9929,"timestamp":1770670799999,"preClose":425.99203,"halted":0,"volume":10915420,"delay":0,"changeRate":0.021129,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":9.000854,"latestTime":"02-09 16:00:00 EST","open":425.0089,"high":435.43948,"low":414.2016,"amount":150552491.2652,"amplitude":0.049855,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.298986,"peRate":-5.062796,"turnoverRate":0.01483,"increases":3,"decrements":1,"flats":1,"marketCap":9276863456,"floatMarketCap":8534856320},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":435.43948,"amplitude":0.049855,"preClose":425.99203,"low":414.2016,"pbRate":"2.298986","latestPrice":434.9929,"volume":10915420,"delay":0,"open":425.0089,"prevYearClose":431.70972,"prevWeekClose":425.992,"prevMonthClose":444.3123,"prevQuarterClose":431.7097,"fiveDayClose":451.8976,"twentyDayClose":445.1537,"sixtyDayClose":429.7061,"secType":"PLATE","market":"US","turnoverRate":0.01483,"peRate":-5.062796,"marketCap":9276863456,"floatMarketCap":8534856320,"timestamp":1770670799999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":3,"down":1,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609593943","title":"Intellia Therapeutics reports inducment grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2609593943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609593943?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:37","pubTimestamp":1770381439,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-reports-inducment-grants-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-reports-inducment-grants-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4535","BK4139","LU1861558580.USD","LU1861559042.SGD","NTLA","BK4556"],"gpt_icon":0},{"id":"2609935325","title":"Intellia Therapeutics Awards Inducement Grants to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2609935325","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609935325?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:30","pubTimestamp":1770381018,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc. has awarded inducement grants to six new employees under its 2024 Inducement Plan. The grants consist of time-based restricted stock units  totaling 30,600 shares of common stock. One-third of the RSUs will vest annually over three years, contingent upon each employee’s continued service with the company. These grants were made under the company’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL5p12hK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4139","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD","NTLA","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BGHQF748.EUR","BK4556","IE00BKPKM429.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","LU1861558580.USD","BK4112","LU1861559042.SGD","BK4585","BK4535","SG9999014005.SGD","BK4588"],"gpt_icon":0},{"id":"2609759365","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609759365","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609759365?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:30","pubTimestamp":1770381000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb.  06, 2026  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/06/3233747/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NTLA","LU1861558580.USD","BK4556","BK4588","BK4585","LU1861559042.SGD","BK4535"],"gpt_icon":0},{"id":"2609587584","title":"Beam Therapeutics announces upcoming board member resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2609587584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609587584?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:39","pubTimestamp":1770327573,"startTime":"0","endTime":"0","summary":"Beam Therapeutics ( ($BEAM) ) has provided an announcement. On January 31, 2026, Beam Therapeutics Inc. announced that board member Dr. Carole Ho h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-announces-upcoming-board-member-resignation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-announces-upcoming-board-member-resignation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU1861559042.SGD","BK4505","BK4556","BK4535","LENZ","BK4139","BEAM","LU1861558580.USD","BK4585","BK4539","BK4611","BK4007"],"gpt_icon":0},{"id":"2609584513","title":"Beam Therapeutics Director Carole Ho Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2609584513","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609584513?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:09","pubTimestamp":1770325775,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc. announced that Carole Ho has resigned from its Board of Directors, effective February 27, 2026. The company stated that her resignation was not due to any disagreement with its operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLjF1lz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4611","BK4556","BK4585","LU1861559042.SGD","BEAM","LU1861558580.USD","BK4535","BK4588"],"gpt_icon":0},{"id":"2609396260","title":"What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2609396260","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609396260?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:46","pubTimestamp":1770212771,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics recently reported detailed Phase 1/2 STAAR study results for its Fabry disease gene therapy, isaralgagene civaparvovec, and confirmed a rolling Biologics License Application submission to the FDA under the Accelerated Approval pathway, supported by kidney function as an intermediate clinical endpoint.\nThe company paired these clinically promising data and regulatory progress with a roughly US$24.82 million follow-on equity raise and a finance leadership change,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sgmo/sangamo-therapeutics/news/what-sangamo-therapeutics-sgmos-fabry-gene-therapy-progress","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sgmo/sangamo-therapeutics/news/what-sangamo-therapeutics-sgmos-fabry-gene-therapy-progress","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4215","PRGS","LU2065732104.USD","BK4139","BK4585","BK4588","BK4556","SGMO","EQR","BK4097"],"gpt_icon":0},{"id":"2608201353","title":"FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang","url":"https://stock-news.laohu8.com/highlight/detail?id=2608201353","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608201353?lang=en_us&edition=fundamental","pubTime":"2026-02-04 14:24","pubTimestamp":1770186280,"startTime":"0","endTime":"0","summary":"FDA lifts clinical hold on Intellia Therapeutics' Phase 3 MAGNITUDE-2 trial of Nexiguran Ziclumeran (Nex-Z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).\nRegulators cleared trial resumption following agreement on study modifications and enhanced safety monitoring.\nThe decision affects Intellia Therapeutics' (NasdaqGM:NTLA) late stage gene editing pipeline and its progress in ATTRv-PN.\n\nIntellia Therapeutics, traded as NasdaqGM:NTLA, is developing CRISPR based...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/fda-clears-intellia-phase-3-attrv-pn-trial-lifting-key-overh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/fda-clears-intellia-phase-3-attrv-pn-trial-lifting-key-overh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4535","BK4556","LU1861558580.USD","BK4585","LU1861559042.SGD","NTLA","BK4588"],"gpt_icon":0},{"id":"2608800059","title":"Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor","url":"https://stock-news.laohu8.com/highlight/detail?id=2608800059","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608800059?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:09","pubTimestamp":1770152959,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL493Pcn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMO","BK4556","BK4139"],"gpt_icon":0},{"id":"2608007408","title":"Sangamo Therapeutics Begins Rolling BLA Submission to FDA for Fabry Disease Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2608007408","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608007408?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:09","pubTimestamp":1770152949,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics Inc. has initiated a rolling submission of its Biologics License Application  to the U.S. Food and Drug Administration  for isaralgagene civaparvovec , a gene therapy candidate for Fabry disease. The submission is being made under the FDA's Accelerated Approval pathway, following the completion of the registrational Phase 1/2 STAAR study. The FDA has agreed that data from this study, specifically the mean annualized estimated glomerular filtration rate  slope at 52 weeks, can serve as the primary basis for approval. No other beneficiary organizations are mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief on February 03,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3bQJZy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","SGMO"],"gpt_icon":0},{"id":"2608039868","title":"BUZZ-U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW","url":"https://stock-news.laohu8.com/highlight/detail?id=2608039868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608039868?lang=en_us&edition=fundamental","pubTime":"2026-02-04 00:02","pubTimestamp":1770134576,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTWEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL6N3YZ126:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMG7P926.USD","LU1934455863.HKD","LU0368265418.SGD","LU0708994859.HKD","LU0070217475.USD","LU0330918003.SGD","LU0757428866.USD","BK4170","LU0058720904.USD","IE00BFXG0V08.USD","IE00BQXX3F31.USD","LU0742534661.SGD","LU1941712264.USD","SG9999015358.SGD","LU2272731782.SGD","LU1861219969.SGD","LU2357305700.SGD","BK4610","LU0289739699.SGD","IE0004445015.USD","IE00BMG7P819.SGD","LU1823568750.SGD","LU1150488218.USD","BK4144","LU1235294995.USD","BK4196","LU0368265764.SGD","LU1732799900.SGD","LU0788109048.HKD","LU0234572021.USD","LU0154245673.USD","LU1720051017.SGD","IE00B7SZLL34.SGD","LU1861220207.SGD","LU0471298777.SGD","LU2237443549.SGD","BK4556","LU0654597011.USD","LU0640476718.USD","IE00B2B36J28.USD","LU2461242641.AUD","LU2023250843.SGD","LU0726765562.USD","LU0012050646.USD","BK4598","LU1280957306.USD","GB00BDT5M118.USD","LU1861214812.USD","IE00BGHQF524.EUR","LU1721429402.USD","SG9999001440.SGD","LU1988902786.USD","LU0096362180.USD","LU0006061336.USD","LU0310800965.SGD","BK4505","LU1430597077.USD","LU0390134368.USD","PLTY","LU0477156953.USD","BK4213","IE00BN8TJ469.HKD","LU1046421795.USD","LU1244550577.SGD","LU0572108347.SGD","LU2237443382.USD","LU1223082196.USD","PLTG","BK4534","PYPG","LU1815333072.USD","LU2089283258.USD","LU0861579265.USD","LU0266512127.USD","LU1267930573.SGD","LU0132412106.USD","LU0345774391.USD","LU2361044949.HKD","LU1941712348.USD","IE00B4R5TH58.HKD","LU0498741114.HKD","LU2237443465.HKD","IE00BBT3K403.USD","IE00B19Z3581.USD","IE00B19Z9P08.USD","LU0029864427.USD","LU2106854487.HKD","BK4166","LU0122379950.USD","LU0098860793.USD","LU0868494708.USD","LU1894683348.USD","LU1303367103.USD","LU0124384867.USD","LU1621768115.EUR","IE00BZ9MQY76.HKD","LU0889566641.SGD","LU0545562505.USD","LU1035773651.USD","LU2129689431.USD","LU2065171402.SGD","LU0648000940.SGD","SG9999002521.SGD","PLTU","LU1861558580.USD","WTW","IE0034235188.USD","LU1267930813.SGD","LU1291159041.SGD","BK4008","LU2517655291.USD","BK4189","LU1116320901.HKD","LU0788109394.HKD","PLTW","LU2089984988.USD","LU0265550359.USD","BK4015","IE00B19Z3B42.SGD","LU1244550494.USD","LU0965508806.USD","BK4108","IE0002141913.USD","LU0162691827.USD","LU2361044865.SGD","LU0154245756.USD","LU0942090050.USD","BK4106","LU2237443895.HKD","LU0070302665.USD","LU0072461881.USD","IE00BYQQ9H92.USD","IE00BZ199S13.USD","LU1201861165.SGD","LU2298322129.HKD","PLOO","BK4017","BK4227","IE00BD6J9T35.USD","IE00BGHQF417.EUR","BK4561","BK4588","SG9999014567.USD","LU1201861249.SGD","IE0004091025.USD","BK4548","IE00BJTD4N35.SGD","LU0433182093.SGD","BK4533","BK4096","LU1815336091.USD","LU0130103400.USD","IE00BMG7P694.USD","LU0957791311.USD","LU1699723380.USD","IE00BJJMRY28.SGD","BK4167","LU2125154778.USD","IE00B3CCJ633.GBP","LU0061474960.USD","LU1150488135.SGD","IE00B7SZL793.SGD","LU1989771016.USD","IE00B7KXQ091.USD","LU2112291526.USD","LU0505663152.USD","LU0300736062.USD","LU0300736492.USD","LU0788109121.HKD","IE00B19Z8X17.USD","LU0107464264.USD","LU1496350171.SGD","BK4134","LU1791807156.HKD","PTIR","BK4524","LU2237443622.USD","BK4581","IE0009355771.USD","BK4182","SG9999015978.USD","BK4539","LU2357125470.USD","LU1496350502.SGD","BK4543","IE00B19Z4B17.USD","LU0985320562.USD","LU1430594728.SGD","LU2381873111.SGD","LU2362540622.SGD","IE00B3CCJ963.GBP","LU1064131342.USD","LU1814569148.SGD","LU0068578508.USD","BK4597","LU1093756168.USD","LU2347655156.SGD","LU2361045086.USD","SG9999014559.SGD","LU1989772840.SGD","BK4023","LU0476273544.USD","SG9999013999.USD","WDC","LU1162221912.USD","SG9999015945.SGD","LU0256863811.USD","LU0965509101.SGD","BK4126","BK4192","LU1861559042.SGD","LU2129689514.USD","IE00B19Z8W00.USD","LU2462611646.USD","PLTD","IE00B2Q91V27.USD","BK4570","BK4532","IE00B1BXHZ80.USD","LU0050427557.USD","IE00BZ1G4Q59.USD","LU1917777945.USD","LU0980610538.SGD","LU2294711713.HKD","LU1548497426.USD","IE00BMG7P702.HKD","LU2125154935.USD","LU1069347547.HKD","SG9999015341.SGD","BK4613","IE00BJJMRZ35.SGD","LU1894683264.USD","IE00BJTD4V19.USD","IE00BJT1NW94.SGD","PLTA","IE00B3S45H60.SGD","BK4535","BK4559","LU2362541513.USD","LU1489326972.SGD","BK4547","SG9999001176.SGD","LU1571399168.USD","LU2249611893.SGD","LU0106831901.USD","LU1093756325.SGD","LU0251142724.SGD","BK4507","LU0251131958.USD","LU1934455194.USD","IE00BJJMRX11.SGD","LU1023059063.AUD","IE00B64QTZ34.USD","SG9999002232.USD","PYPY","LU0724618789.USD","SOFX","LU1621767810.EUR","BK4137","LU2065171311.SGD","IE0002270589.USD","LU0957808578.USD","BK4585","BK4549","IE00B19Z9Z06.USD","BK4187","LU0061475181.USD","PLT","LU0006306889.USD","LU1989772923.USD","LU0724618433.USD","LU0055631609.USD","IE0004086264.USD","LU0106261372.USD","LU2237438978.USD","LU0786609619.USD","LU1066051811.HKD","LU0417517546.SGD","LU1223082519.USD","LU0612318971.USD","BK4590","LU2362541273.HKD","LU0130102774.USD","LU1037948897.HKD","LU2023250504.SGD","LU2065169927.USD","LU0630314457.HKD","LU0130517989.USD","SG9999014575.USD","LU1223083913.SGD","LU1066051225.USD","BK4554","LU0345780521.USD","LU0128525689.USD","LU1815336760.USD","IE0031619046.USD","PLYY","LU2211814178.USD","LU2133065610.SGD","LU0792757196.USD","SG9999015986.USD","LU1721429741.USD","SG9999001176.USD","BK4512","LU1228905540.USD","SG9999015952.SGD","LU1023059493.AUD","BK4567","LU1061106388.HKD","LU0266512473.USD","LU2129689605.HKD","LU0048573561.USD","LU1992135472.HKD","LU2264538146.SGD","BR","IE00BMG7P587.USD","IE00B66KJ199.SGD","LU0072463663.USD","LU1621768206.USD","BK4007","BK4226","LU1929549753.HKD","SG9999002224.SGD","IE00BLSP4452.SGD","LU0965509010.AUD","LU0128525929.USD","LU1978683503.SGD","LU0011850046.USD","LU0477156797.USD","LU2279689827.SGD","BK4131","LU1074936037.SGD","LU2517655374.HKD","LU1037948541.HKD","LU2506951792.HKD","LU0210533765.USD","LU0345780950.USD","BK4139","LU0266013472.USD","LU2237443978.SGD","BK4110","LU1267930227.SGD","LU1585245621.USD","LU2347655073.USD","LU0385154629.USD","LU0081259029.USD","LU1066051498.USD","LU1718418525.SGD","LU2272731600.USD","IE00BLSP4239.USD","LU1668664300.SGD","LU1228905037.USD","LU2360107671.USD","LU0320765489.SGD","LU1861217088.USD","IE00BKVL7J92.USD","SGXZ57979304.SGD","IE00BFSS7M15.SGD","IE00BQXX3D17.EUR","LU0795875086.SGD","LU0278409577.USD","LU1732800096.USD","LU0238689110.USD","LU1621767737.EUR","LU1116320737.USD","LU2023251221.USD","BK4551","LU0203347892.USD","LU0788108826.HKD","LU2384288077.EUR","LU0912757837.SGD","BK4504","LU0075056555.USD","LU0985489474.SGD","LU2360032135.SGD","IE00B3T34201.USD","LU0878866978.SGD","LU1983299246.USD","LU0496367417.USD","SG9999001143.SGD","LU0345781412.USD","LU0498741890.SGD","LU0203345920.USD","LU1992135399.USD","LU0208291251.USD","IE00B19Z9505.USD","LU1244550221.USD","BK4177","BK4209","BK4516","LU0122376428.USD","LU0310800379.SGD","LU0345774631.USD","BK4500","LU0795875169.SGD","IE0009354923.USD","LU1642822529.SGD","SG9999014542.SGD","IE00BFSS8Q28.SGD","LU1883866441.USD","LU2098885051.SGD","BK4121","PLTZ","LU2468319806.SGD","BK4566","IE00BFTCPJ56.SGD","LU0052756011.USD","LU0648001328.SGD","LU2324357040.USD","IE000M9KFDE8.USD","LU1974910355.USD","LU0170899867.USD","IE00BSNM7G36.USD","LU0965509283.SGD","LU1934455277.USD","LU2089284900.SGD","IE00BLDYK493.USD","LU0823414551.USD","LU2065170008.USD","LU1720051108.HKD","BK4592","LU1057294990.SGD","IE00B2PGVK34.USD","LU0211331839.USD","LU0868494617.USD","LU0130518102.USD","LU0432979614.USD","LU2517655028.SGD","LU1066053197.SGD","BK4527","LU0158827948.USD","LU0320765646.SGD","LU0612318385.USD","IE00B894F039.SGD","LU2498475776.HKD","LU0823414478.USD","LU0265550946.USD","LU2360107325.USD","LU0456854461.SGD","IE00B775SV38.USD","IE00BQXX3C00.GBP","BK4550","LU2211817866.USD","LU0106261612.USD","LU0444971666.USD","LU0444973449.USD","LU0345780281.USD","BK4173","BK4201","BK4138"],"gpt_icon":1},{"id":"2608872095","title":"Sangamo says principal financial officer Prathyusha Duraibabu terminated","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872095","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608872095?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:22","pubTimestamp":1770128523,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Sangamo (SGMO) announced that on February 2, the employment of Prathyusha Duraibabu, the company’s principal financial offi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sangamo-says-principal-financial-officer-prathyusha-duraibabu-terminated-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sangamo-says-principal-financial-officer-prathyusha-duraibabu-terminated-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4139","SGMO"],"gpt_icon":0},{"id":"2608787208","title":"Sangamo names Nikunj Jain as interim CFO, principal financial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608787208","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608787208?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:21","pubTimestamp":1770128507,"startTime":"0","endTime":"0","summary":"09:15 EST Sangamo (SGMO) names Nikunj Jain as interim CFO, principal financial officer Published first on TheFly – the ultimate source for real-tim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sangamo-names-nikunj-jain-as-interim-cfo-principal-financial-officer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sangamo-names-nikunj-jain-as-interim-cfo-principal-financial-officer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4139","SGMO"],"gpt_icon":0},{"id":"2608987209","title":"Sangamo prices 35.2M shares at 47.19c in underwritten offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2608987209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608987209?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:15","pubTimestamp":1770128144,"startTime":"0","endTime":"0","summary":"Sangamo (SGMO) Therapeutics announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded wa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sangamo-prices-35-2m-shares-at-47-19c-in-underwritten-offering-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sangamo-prices-35-2m-shares-at-47-19c-in-underwritten-offering-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMO","BK4556"],"gpt_icon":0},{"id":"2608872947","title":"Sangamo Therapeutics Prices $25 Million Offering with Warrants and Share Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872947","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608872947?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:10","pubTimestamp":1770127854,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics Inc. announced the pricing of an underwritten offering that includes 35,190,292 shares of common stock and pre-funded warrants to purchase 17,787,033 shares of common stock, along with accompanying warrants to purchase 52,977,325 shares of common stock. Each share or pre-funded warrant is being sold together with a warrant to purchase one share of common stock. The accompanying warrants have an exercise price of $0.4719 per share, become exercisable six months after issuance, and expire five and a half years from issuance. Additionally, Sangamo has agreed to reduce the exercise price on certain outstanding warrants and extend their term. The gross proceeds from the offering are expected to be approximately $25 million before expenses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL1ngjp5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","BK4585","LU2095319765.USD","LU2210150020.SGD","SGMO","SG9999014005.SGD","SG9999014021.USD","NDAQ","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4556","IE00B3QW5Z07.USD","BK4112","BK4139"],"gpt_icon":0},{"id":"2608872992","title":"Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608872992?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:10","pubTimestamp":1770127843,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA3RFXCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","SGMO","BK4139"],"gpt_icon":0},{"id":"2608087232","title":"BRIEF-Sangamo Therapeutics Inc - On Feb 2, Prathyusha Duraibabu Terminated As Principal Financial Officer - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2608087232","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608087232?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:03","pubTimestamp":1770127398,"startTime":"0","endTime":"0","summary":"BRIEF-Sangamo Therapeutics Inc - On Feb 2, Prathyusha Duraibabu Terminated As Principal Financial Officer - SEC FilingFeb 3  - Sangamo Therapeutics Inc SGMO.O:SANGAMO THERAPEUTICS INC - ON FEB 2, PRATHYUSHA DURAIBABU TERMINATED AS PRINCIPAL FINANCIAL OFFICER - SEC FILINGSANGAMO THERAPEUTICS INC - NIKUNJ JAIN APPOINTED INTERIM CHIEF FINANCIAL OFFICER - SEC FILINGSource text: [ID:n0001001233-26-000002]Further company coverage: SGMO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ139:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMO","BK4556"],"gpt_icon":0},{"id":"2608255874","title":"Sangamo Therapeutics Inc - on Feb 2, Prathyusha Duraibabu Terminated as Principal Financial Officer - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2608255874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608255874?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:57","pubTimestamp":1770127030,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ139:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMO","BK4556"],"gpt_icon":0},{"id":"2608742548","title":"Sangamo Therapeutics ernennt Nikunj Jain zum Interim-Finanzchef","url":"https://stock-news.laohu8.com/highlight/detail?id=2608742548","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608742548?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:56","pubTimestamp":1770127001,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics Inc. hat bekanntgegeben, dass die bisherige Finanzchefin Prathyusha Duraibabu das Unternehmen verlassen hat. Nikunj Jain, bislang Vice President Finance und Corporate Controller, übernimmt ab sofort interimistisch die Funktion des Chief Financial Officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL5t2pPc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","SGMO"],"gpt_icon":0},{"id":"2608100299","title":"Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608100299","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608100299?lang=en_us&edition=fundamental","pubTime":"2026-02-01 13:19","pubTimestamp":1769923184,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) attracted investor attention after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial. This decision allows enrollment to resume under tighter liver safety monitoring protocols.\nSee our latest analysis for Intellia Therapeutics.\nThe FDA decision arrives after a sharp run, with a 30 day share price return of 42.78% and a year to date share price return of 42.78%, yet the 3 year total shareholder return of 69.58% and 5 year total shareholder return...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/assessing-intellia-therapeutics-ntla-valuation-after-fda-lif","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/assessing-intellia-therapeutics-ntla-valuation-after-fda-lif","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861559042.SGD","BK4139","NTLA","BK4556","BK4588","LU1861558580.USD","BK4585","BK4535"],"gpt_icon":0},{"id":"2607071202","title":"IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed","url":"https://stock-news.laohu8.com/highlight/detail?id=2607071202","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607071202?lang=en_us&edition=fundamental","pubTime":"2026-01-31 21:00","pubTimestamp":1769864441,"startTime":"0","endTime":"0","summary":"Insiders have been trading these 5 stocks: (($IBM)), (($PG)), (($GME)), (($CRSP)) and (($AGNC)). Here is a breakdown of their recent trades and the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/ibm-pg-gamestop-crispr-agnc-insider-moves-exposed?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/ibm-pg-gamestop-crispr-agnc-insider-moves-exposed?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BLSP4452.SGD","IBM","LU1280957306.USD","LU0098860793.USD","CRSP","BK4550","LU0689626769.HKD","LU1585245621.USD","BK4577","BK4018","BK4534","LU1868837136.USD","IE00BLSP4239.USD","IE00B1XK9C88.USD","LU0237698245.USD","BK4134","BK4139","LU0094547139.USD","LU1861558580.USD","LU2552382058.USD","SG9999002232.USD","SG9999002224.SGD","LU1674673691.USD","BK4611","LU1894683348.USD","BK4504","LU2242652126.USD","BK4585","LU1674673428.USD","AGNC","BK4588","BK4575","BK4559","LU0640476718.USD","IE00BBT3K403.USD","LU1162221912.USD","LU2097829019.USD","LU1868837300.USD","SG9999014542.SGD","LU1880398471.USD","BK4579","LU0234572021.USD","SG9999014575.USD","BK4556","LU1778281490.HKD","LU2129689431.USD","LU0061475181.USD","BK4558","LU0234570918.USD","IE00B3T34201.USD","LU1914381329.SGD","LU2552382132.HKD","LU0868494708.USD","LU0321505439.SGD","LU1883839398.USD","BK4602","BK4533","LU0320765646.SGD","GME","SG9999014567.USD","LU2552382215.SGD","IE00BWXC8680.SGD","LU1868836914.USD","LU2242646821.SGD","LU0323591593.USD","SG9999015341.SGD","LU1894683264.USD","BK4612","IE000M9KFDE8.USD","LU2129689605.HKD","LU2129689514.USD","LU0124676726.USD","PG","BK4581","LU0942090050.USD","BK4547","LU0868494617.USD","LU0321505868.SGD","BK4538","BK4567","LU1929549753.HKD","GB00BDT5M118.USD","BK4110","LU1868836591.USD","LU1066051498.USD","SG9999015358.SGD","LU1861559042.SGD","SG9999001440.SGD","LU1868836757.USD","LU1066053197.SGD","IE00BN8TJ469.HKD","SG9999014559.SGD","LU1430594728.SGD","LU0096364046.USD","LU1880398554.USD","BK4076","BK4543"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}